Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas
Emad Elquza, Hani M. Babiker, Krisha J. Howell, Andrew I. Kovoor, Thomas David Brown, Hitendra Patel, Steven A. Malangone, Mitesh J. Borad, Tomislav Dragovich
ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.
Cancer Investigation
gastroesophageal carcinoma
Fingerprint Dive into the research topics of 'Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas'. Together they form a unique fingerprint.
Pemetrexed Medicine & Life Sciences
Esophagogastric Junction Medicine & Life Sciences
Maximum Tolerated Dose Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
Safety Medicine & Life Sciences
Elquza, E., Babiker, H. M., Howell, K. J., Kovoor, A. I., Brown, T. D., Patel, H., Malangone, S. A., Borad, M. J., & Dragovich, T. (2016). Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. Cancer Investigation, 34(2), 57-63. https://doi.org/10.3109/07357907.2015.1108426
Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. / Elquza, Emad; Babiker, Hani M.; Howell, Krisha J.; Kovoor, Andrew I.; Brown, Thomas David; Patel, Hitendra; Malangone, Steven A.; Borad, Mitesh J.; Dragovich, Tomislav.
In: Cancer Investigation, Vol. 34, No. 2, 07.02.2016, p. 57-63.
Elquza, E, Babiker, HM, Howell, KJ, Kovoor, AI, Brown, TD, Patel, H, Malangone, SA, Borad, MJ & Dragovich, T 2016, 'Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas', Cancer Investigation, vol. 34, no. 2, pp. 57-63. https://doi.org/10.3109/07357907.2015.1108426
Elquza E, Babiker HM, Howell KJ, Kovoor AI, Brown TD, Patel H et al. Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. Cancer Investigation. 2016 Feb 7;34(2):57-63. https://doi.org/10.3109/07357907.2015.1108426
Elquza, Emad ; Babiker, Hani M. ; Howell, Krisha J. ; Kovoor, Andrew I. ; Brown, Thomas David ; Patel, Hitendra ; Malangone, Steven A. ; Borad, Mitesh J. ; Dragovich, Tomislav. / Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. In: Cancer Investigation. 2016 ; Vol. 34, No. 2. pp. 57-63.
@article{ce26be1e3e57419db682a61f456364b8,
title = "Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas",
abstract = "ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.",
keywords = "Pemetrexed, cisplatin, gastroesophageal carcinoma, radiation",
author = "Emad Elquza and Babiker, {Hani M.} and Howell, {Krisha J.} and Kovoor, {Andrew I.} and Brown, {Thomas David} and Hitendra Patel and Malangone, {Steven A.} and Borad, {Mitesh J.} and Tomislav Dragovich",
note = "Publisher Copyright: {\textcopyright} 2016 Taylor & Francis Group, LLC. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",
journal = "Cancer Investigation",
T1 - Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas
AU - Elquza, Emad
AU - Babiker, Hani M.
AU - Howell, Krisha J.
AU - Kovoor, Andrew I.
AU - Brown, Thomas David
AU - Patel, Hitendra
AU - Malangone, Steven A.
AU - Borad, Mitesh J.
N1 - Publisher Copyright: © 2016 Taylor & Francis Group, LLC. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.
N2 - ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.
AB - ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.
KW - Pemetrexed
KW - cisplatin
KW - gastroesophageal carcinoma
KW - radiation
JO - Cancer Investigation
JF - Cancer Investigation